Samsung Bioepis and Organon (OGN) announced that the FDA has designated the Hadlima high- and low-concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira. These interchangeability designations follow the interchangeability designation received for the Hadlima low-concentration prefilled syringe and single-dose vial in June 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: